[PDF] Top 20 Encuadres retórico-políticos en la ley de víctimas y restitución de tierras en Colombia
Has 10000 "Encuadres retórico-políticos en la ley de víctimas y restitución de tierras en Colombia" found on our website. Below are the top 20 most common "Encuadres retórico-políticos en la ley de víctimas y restitución de tierras en Colombia".
Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer.
... requires cells to contain a 4 0 ,6-diamidino-2-phenylindole positive (DAPI)-intact nucleus, lack expression of the haematopoietic marker CD45, express epithelial cell adhesion molecule (EpCAM) and cytokeratin ... See full document
6
Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts.
... identify resistant disease and guide early treatment switches remains, however, an unmet clinical ...of circulating tumour cells as a prognostic indicator for advanced prostate ... See full document
53
Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer
... of metastatic CRPC patients with different CTC load and prognosis by using comprehensive gene expression analysis of blood ...of cancer cells compared to normal ... See full document
89
Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.
... whether patients with lower levels of AR-V7 mRNA still benefit from novel endocrine agents ...that patients with CTC+/AR-V7+ tests have significantly higher AR-V7 protein expression in matched mCRPC ... See full document
8
Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration- resistant prostate cancer: A report from the PETRUS prospective study
... in cancer progression, and recurrent ETS gene fusions has been found in 50- 70% of prostate cancer ...mCRPC patients, though these patients derived the greatest benefit from abiraterone ... See full document
14
Circulating tumor cells in patients with metastatic castration resistant prostate cancer: exploratory findings at a tertiary referral hospital
... anti- cancer regimens in mCRPC patients, overall survival is an important endpoint, requiring reliable prognostic criteria to adjust for the heterogeneity of the ... See full document
36
Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration resistant prostate cancer
... from patients with mCRPC for Ima- geStreamX analysis was centrifuged at 450 G for 10 minutes and washed with ...PBS. Cells were blocked using FcR Block- ing Reagent (Miltenyi Biotec, 1:10) for 10 ...6 ... See full document
12
Abiraterone acetate after progression with enzalutamide in chemotherapy naïve patients with metastatic castration resistant prostate cancer: a multi center retrospective analysis
... in patients with mCRPC, and have, consequently, been introduced into daily clinical ...mCRPC patients, regardless of prior docetaxel treatment, based on positive results from a large randomized phase 3 ... See full document
5
Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide.
... Disclosures/Conflicts of Interest: GA has received honoraria, consulting fees or travel support from Astellas, Medivation, Janssen, Millennium Pharmaceuticals, Ipsen, Ventana, Bayer, Essa Pharma, Abbott Labs, Novartis, ... See full document
80
Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer.
... the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) based on a 62.. demonstrated survival benefit and a favorable tolerability profile in both t[r] ... See full document
49
Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens
... The most common adverse events of enzalutamide reported in the AFFIRM, PREVAIL, TERRAIN, and STRIVE clinical studies were fatigue, back pain, and hot flushes. Seizure is a risk with enzalutamide treatment; there- fore, ... See full document
6
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
... 353 patients (34% [184/546] of the abiraterone group, 31% [169/542] of the prednisone group) were receiving concomitant ...353 patients, 93% were treated with zoledronic acid, 6% with denosumab, and the ... See full document
28
Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer
... Prostate cancer (PCa) is the most frequently diagnosed noncutaneous malignancy in elderly men and is the second leading cause of cancer-related death in Western countries ...of patients have ... See full document
51
Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency.
... the prostate with extensive nodal, lung, and bone metastatic disease and a relatively low prostate-specific antigen (PSA: ...a cancer syndrome ...of prostate adenocarcinoma ... See full document
10
A prospective study to evaluate the intra-individual reproducibility of bone scans for quantitative assessment in patients with metastatic prostate cancer
... BSI was calculated using the commercially available soft- ware EXINI bone BSI version 2 (EXINI Diagnostics AB, Lund Sweden). The automated method of calculating BSI has been described in detail elsewhere [7] and was ... See full document
170
Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review.
... 36 patients participating in the open-label study, 96% reported adverse events that were grade 1 or 2, with the most frequently reported adverse events being diar- rhea (17%), nausea (17%), and fatigue ... See full document
20
The Ongoing Challenges of Targeting the Androgen Receptor.
... 4. Buttigliero C, Tucci M, Bertaglia V, Vignani F, Bironzo P, Di Maio M, Scagliotti GV. Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration ... See full document
7
Prognostic and predictive clinical factors in patients with metastatic castration resistant prostate cancer treated with cabazitaxel
... of patients enrolled in a prospective study. The small number of patients included in this study could limit its statistical power to detect smaller ...most patients included in this study were ECOG ... See full document
22
Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer
... among patients given enzalutamide and ...of patients who crossed over and received subsequent ...However, patients with ECOG score 2, as well as those who had received two or more prior chemotherapy ... See full document
22
Health economic impact of liquid biopsies in cancer management.
... tumor cells in blood was first observed in 1869 (10); a validated assay for reliable CTC measurement was introduced in 2004 (11) and results from multicenter prospective studies in metastatic breast and ... See full document
35
Related subjects